Moderna Shares Reach New High Amid Focus Beyond COVID Vaccines
publishers 5articles 5first reported 23 Sep, 21:30 UTC
Moderna shares reached a new high as investors focused on the company’s efforts beyond COVID-19 vaccines, according to Barron’s. Yahoo Finance reported that the stock was on track to rank as September’s second-best performer in the S&P 500, while noting that five smaller health-care companies had posted stronger gains.
Other coverage centered on Moderna’s innovation strategy and its cancer-vaccine work. The Wall Street Journal described CEO Stéphane Bancel’s approach to innovation as realistic, while Trefis examined whether the stock’s cancer-vaccine-driven rally could have been anticipated. Benzinga also reported that Moderna shares were drawing attention in after-hours trading alongside Merck.
HOW THIS STORY WAS MADE
Written from 5 articles, headlines and summaries only; 5 independent newsrooms once syndicated copies count as one; this version written within the hour the record first saw the story; the editor kept it as written.
- Publishers
- 5
- Source articles
- 5
- Given to the writer
- 5, headlines and summaries only
- Independent newsrooms
- 5
- This version written
- within the hour the record first saw the story
- Second model (editor)
- kept as written
- Publication gate
- passed
- Human review
- none
Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →